Varian Medical Systems, Inc. (VAR) Position Cut by Disciplined Growth Investors Inc. MN

Disciplined Growth Investors Inc. MN trimmed its position in Varian Medical Systems, Inc. (NYSE:VAR) by 2.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 754,668 shares of the medical equipment provider’s stock after selling 17,975 shares during the quarter. Varian Medical Systems accounts for 1.8% of Disciplined Growth Investors Inc. MN’s holdings, making the stock its 23rd largest holding. Disciplined Growth Investors Inc. MN owned 0.82% of Varian Medical Systems worth $92,560,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in VAR. Ladenburg Thalmann Financial Services Inc. boosted its position in Varian Medical Systems by 27.7% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,968 shares of the medical equipment provider’s stock valued at $218,000 after buying an additional 427 shares in the last quarter. Baird Financial Group Inc. boosted its position in Varian Medical Systems by 5.7% in the first quarter. Baird Financial Group Inc. now owns 8,006 shares of the medical equipment provider’s stock valued at $981,000 after buying an additional 430 shares in the last quarter. Cambridge Investment Research Advisors Inc. boosted its position in Varian Medical Systems by 12.6% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 3,994 shares of the medical equipment provider’s stock valued at $444,000 after buying an additional 448 shares in the last quarter. MUFG Americas Holdings Corp boosted its position in Varian Medical Systems by 45.2% in the fourth quarter. MUFG Americas Holdings Corp now owns 1,713 shares of the medical equipment provider’s stock valued at $190,000 after buying an additional 533 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. boosted its position in Varian Medical Systems by 17.6% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 3,613 shares of the medical equipment provider’s stock valued at $402,000 after buying an additional 540 shares in the last quarter. 93.74% of the stock is currently owned by institutional investors and hedge funds.

VAR has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Varian Medical Systems from a “buy” rating to a “hold” rating in a research report on Wednesday, March 28th. ValuEngine upgraded shares of Varian Medical Systems from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Royal Bank of Canada set a $115.00 price target on shares of Varian Medical Systems and gave the stock a “hold” rating in a report on Tuesday, April 10th. Finally, TheStreet upgraded shares of Varian Medical Systems from a “c” rating to a “b” rating in a report on Wednesday, April 25th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $115.13.

Shares of Varian Medical Systems opened at $122.17 on Monday, Marketbeat.com reports. The firm has a market cap of $11.18 billion, a PE ratio of 33.94, a price-to-earnings-growth ratio of 3.40 and a beta of 0.85. Varian Medical Systems, Inc. has a 52 week low of $95.23 and a 52 week high of $130.29.

Varian Medical Systems (NYSE:VAR) last issued its quarterly earnings results on Wednesday, April 25th. The medical equipment provider reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.11. The company had revenue of $729.90 million for the quarter, compared to analyst estimates of $685.86 million. Varian Medical Systems had a net margin of 4.77% and a return on equity of 27.99%. Varian Medical Systems’s revenue was up 10.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.89 earnings per share. research analysts forecast that Varian Medical Systems, Inc. will post 4.5 EPS for the current year.

In related news, EVP Kolleen T. Kennedy sold 699 shares of the business’s stock in a transaction on Tuesday, April 10th. The shares were sold at an average price of $120.33, for a total value of $84,110.67. Following the transaction, the executive vice president now owns 27,361 shares in the company, valued at $3,292,349.13. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP John W. Kuo sold 1,328 shares of the business’s stock in a transaction on Monday, April 16th. The shares were sold at an average price of $121.94, for a total transaction of $161,936.32. Following the completion of the transaction, the senior vice president now owns 30,708 shares in the company, valued at approximately $3,744,533.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,053 shares of company stock worth $484,127. 0.78% of the stock is owned by company insiders.

Varian Medical Systems Profile

Varian Medical Systems, Inc designs, manufactures, sells, and services medical devices and software products for treating cancer and other medical conditions worldwide. It operates through two segments, Oncology Systems and Varian Particle Therapy. The Oncology Systems segment provides hardware and software products for treating cancer with radiotherapy, fixed field intensity-modulated radiation therapy, image-guided radiation therapy, volumetric modulated arc therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy.

Institutional Ownership by Quarter for Varian Medical Systems (NYSE:VAR)

Receive News & Ratings for Varian Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Varian Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply